The goal of this retrospective observational study is to characterize multiple myeloma (MM) patients (by collecting demographics, disease characteristics and treatment history data) treated in first or second relapse with belantamab mafodotin combinations under compassionate use conditions.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Patient year of birth
Timeframe: 18 months
Patient sex
Timeframe: 18 months
Patient weight
Timeframe: 18 months
Disease diagnosis date
Timeframe: 18 months
Disease Interational Score System status at diagnosis
Timeframe: 18 months
Disease type of MM (secretory or oligosecretory)
Timeframe: 18 months
Disease type of immunoglobulin
Timeframe: 18 months
Disease ECOG status
Timeframe: 18 months
Disease extramedullar disease at relapse
Timeframe: 18 months
Disease presentation of plasma cell leukemia
Timeframe: 18 months
Disease high-risk
Timeframe: 18 months
Disease kidney function pre-belantamab infusion by creatinine clearance
Timeframe: 18 months
Disease kidney function pre-belantamab infusion by serum creatinine
Timeframe: 18 months
Disease kidney failure at disease progression
Timeframe: 18 months
Disease tumoral load pre-belantamab infusion by circulating cells
Timeframe: 18 months
Disease tumoral load pre-belantamab infusion by serum beta-2-microglobulin
Timeframe: 18 months
Disease presence of lytic lesions
Timeframe: 18 months
Disease previous anti-MM treatments
Timeframe: 18 months
Disease number of previous anti-MM treatments and treatment response
Timeframe: 18 months
Disease first line treatment
Timeframe: 18 months
Disease date of first relapse
Timeframe: 18 months
Disease date of second line treatment (if applies)
Timeframe: 18 months
Disease date of second relapse (if applies)
Timeframe: 18 months
Patient comorbidities
Timeframe: 18 months